neoantigen vaccine + tislelizumab + gemcitabine + capecitabine

Neoantigen vaccine + anti-PD1 + chemotherapy refers to an investigational combination regimen being evaluated as an adjuvant treatment for resected pancreatic ductal adenocarcinoma (PDAC). In the specific context of clinical trial NCT06344156, the regimen consists of a personalized neoantigen vaccine (referred to as Neovax), the anti-PD-1 monoclonal antibody tislelizumab (Tevimbra), and a chemotherapy backbone of gemcitabine and capecitabine (GemCap). The personalized vaccine is designed to stimulate a T-cell response against patient-specific tumor mutations, while tislelizumab prevents immune evasion by blocking the PD-1/PD-L1 pathway. The chemotherapy component serves to eliminate residual disease and potentially enhance the immunogenicity of the tumor. This multi-modal approach aims to improve recurrence-free survival in patients with high-risk resected pancreatic cancer.

Brand names

Tevimbra

Other names

Neoantigen Vaccine + Anti-PD1 + ChemotherapyNeovax + tislelizumab + GemCap